REAL-WORLD USAGE OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH PSORIATIC ARTHRITIS IN GERMANY

被引：0

作者：

Song, J. ^{[1
,2
]}

Anjohrin, S. ^{[3
]}

Abe, C. ^{[4
]}

Banefelt, J. ^{[5
]}

Rieem, Dun A. ^{[5
]}

Picker, N. ^{[6
]}

Kromer, D. ^{[7
]}

Fuchs, A. ^{[8
]}

Hahn, P. ^{[9
]}

Welby, S. ^{[10
]}

机构：

[1] UCB Pharma, Brussels, Belgium

[2] Karolinska Inst, Stockholm, Sweden

[3] UCB Pharma, Brussels, Belgium

[4] Karolinska Inst & Quantify Res, Stockholm, Sweden

[5] Quantify Res, Stockholm, Sweden

[6] Cytel, Wismar, Germany

[7] Cytel, Berlin, Germany

[8] AOK PLUS, Dresden, Germany

[9] Inst Pharmakookonomie & Arzneimittell IPAM, Wismar, Germany

[10] UCB Pharma, Anderlecht, Belgium

来源：

VALUE IN HEALTH | 2023年 / 26卷 / 12期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

HSD60

引用

页码：S305 / S305

页数：1

共 50 条

[41] ADHERENCE TO BIOLOGIC AND CONVENTIONAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Mishra, P.
VALUE IN HEALTH, 2018, 21 : S198 - S198
[42] REAL-WORLD USE OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN US PATIENTS WITH ANKYLOSING SPONDYLITIS: PERSISTENCE, FACTORS ASSOCIATED WITH DISCONTINUATION, AND DOSING PATTERNS
Dubreuil, M.
Walsh, J. A.
Deodhar, A.
Gensler, L. S.
Curtis, J. R.
Anjohrin, S.
Pilipczuk, O.
Tepie, Feudjo M.
Beaty, S.
Morup, M.
Taieb, V
Welby, S.
VALUE IN HEALTH, 2023, 26 (06) : S386 - S387
[43] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
Monchablon, Clelia
Gonde, Henri
Pouplin, Sophie
Varin, Remi
Vittecoq, Olivier
Lequerre, Thierry
CLINICAL RHEUMATOLOGY, 2020, 39 (01) : 207 - 216
[44] Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis
Haibel, H.
Specker, C.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (04) : S159 - S163
[45] INFECTIOUS COMPLICATIONS AS A REASON FOR THE CANCELLATION OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
Aronova, E.
Gridneva, G.
Kudryavtceva, A.
Dydykina, I.
Lukina, G.
OSTEOPOROSIS INTERNATIONAL, 2021, 32 (SUPPL 1) : S250 - S250
[46] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
Clélia Monchablon
Henri Gondé
Sophie Pouplin
Rémi Varin
Olivier Vittecoq
Thierry Lequerré
Clinical Rheumatology, 2020, 39 : 207 - 216
[47] Ovarian Reserve in Children with Juvenile Idiopathic Arthritis Using Biologic Disease-Modifying Anti-Rheumatic Drugs
Ozer, Yavuz
Yildiz, Mehmet
Turan, Hande
Tarcin, Gurkan
Aydin, Dilek Bingol
Gunalp, Aybuke
Haslak, Fatih
Konte, Elif Kilic
Aslan, Esma
Koker, Oya
Bayramoglu, Elvan
Sahin, Sezgin
Adrovic, Amra
Barut, Kenan
Kasapcopur, Ozgur
Evliyaoglu, Olcay
HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 : 400 - 400
[48] Ovarian reserve in children with juvenile idiopathic arthritis using biologic disease-modifying anti-rheumatic drugs
Ozer, Yavuz
Yildiz, Mehmet
Turan, Hande
Tarcin, Gurkan
Aydin, Dilek Bingol
Gunalp, Aybuke
Haslak, Fatih
Konte, Elif Kilic
Aslan, Esma
Koker, Oya
Bayramoglu, Elvan
Sahin, Sezgin
Adrovic, Amra
Barut, Kenan
Kasapcopur, Ozgur
Evliyaoglu, Olcay
CLINICAL RHEUMATOLOGY, 2024, 43 (01) : 399 - 406
[49] Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis
Roy Fleischmann
Clinical Rheumatology, 2021, 40 : 4369 - 4372
[50] Australian recommendations on tapering of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in inflammatory arthritis
Whittle, Samuel L.
Glennon, Vanessa
Johnston, Renea, V
Avery, Jodie C.
Bell, J. Simon
Brennan, Sue E.
Fong, Christopher
Hissaria, Pravin
Horgan, Ben
O'Neill, Sean
Pisaniello, Huai Leng
Trevena, Lyndal
Whittaker, Glen A.
Wluka, Anita
Buchbinder, Rachelle
INTERNAL MEDICINE JOURNAL, 2022, 52 (10) : 1799 - 1805

← 1 2 3 4 5 →